Exelixis, Inc.

EXEL Healthcare Biotechnology

Exelixis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 6.98% from fiscal 2024.

Revenue
+10.2%
EPS
+22.2%
Free cash flow
−4.83%

Quarter to September 2026, against a year earlier

69.79 1.08 +1.57%
Market cap
$16.8B
P/E
19.9×
Fwd P/E
20.2×
Dividend yield
—
F-score
7/9
Altman Z
12.68
Beneish M
−2.61
Dividend safety
n/a
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Piotroski F-Score
6 7 7 4 4 6 5 7 9 7
P/E ratio
0.00 59.25 8.55 16.62 54.24 24.87 28.60 36.63 18.50 15.17
Altman Z-Score
0.33 12.76 27.49 17.32 15.41 10.00 6.54 7.86 10.04 12.68
P/S ratio
19.28 20.37 6.86 5.51 6.27 4.01 3.25 4.16 4.45 5.13
P/FCF ratio
17.67 63.74 15.31 10.37 34.63 17.10 23.38 44.69 15.24 14.10
Altman Z″-Score (non-manufacturers)
(8.78) (2.89) 13.73 12.24 11.11 9.94 7.65 5.76 6.99 7.69
P/Operating CF
43.36 172.79 56.02 33.74 185.83 59.68 71.12 720.21 40.20 35.69
Beneish M-Score
(0.42) 0.82 (0.32) (3.12) (2.62) (2.33) (2.64) (2.62) (2.67) (2.61)
P/B ratio
41.32 32.35 4.55 3.16 3.29 2.60 2.11 3.36 4.30 5.51
EV/Sales
17.51 19.55 6.06 4.65 5.07 3.01 2.46 3.63 3.95 4.68
EV/EBITDA
0.00 52.94 11.67 11.92 41.98 14.36 17.79 33.78 13.53 12.06
EV/FCF
16.05 61.16 13.53 8.76 28.01 12.81 17.65 38.99 13.52 12.87
Current Ratio
1.74 4.21 8.50 7.08 7.06 5.43 4.99 3.34 3.63 3.56
Net Debt/EBITDA
22.46 (2.23) (1.56) (2.26) (10.12) (4.89) (5.88) (5.06) (1.75) (1.18)
Debt/Equity
0.00 0.05 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
ROE
272.77% 82.41% 87.77% 21.59% 6.27% 11.30% 7.76% 8.74% 23.13% 35.53%
ROA
(15.13%) 24.66% 66.43% 19.41% 5.56% 9.72% 6.41% 6.91% 17.70% 27.02%
ROIC
0.00% 0.00% 46.17% 27.70% 10.23% 24.10% 10.67% 8.42% 33.35% 49.46%
Return on Tangible Assets
(34.71%) 39.00% 81.91% 34.99% 8.55% 14.43% 12.97% 19.74% 44.06% 68.85%
Average Days of Receivables
77.11 65.50 69.58 44.91 59.46 71.90 48.66 47.35 44.67 45.14
Earnings Yield
(2.38%) 1.69% 11.69% 6.02% 1.84% 4.02% 3.50% 2.73% 5.41% 6.59%
Free Cash Flow Yield
5.66% 1.57% 6.53% 9.64% 2.89% 5.85% 4.28% 2.24% 6.56% 7.09%
Free Cash Flow per Share
0.83 0.49 1.28 1.70 0.58 1.07 0.70 0.54 2.19 3.11
Book value per Share
0.36 0.97 4.32 5.57 6.10 7.02 7.74 7.12 7.74 7.96
Free Cash Flow
208.80 144.63 382.73 514.12 178.64 336.58 224.16 170.36 633.79 844.34
EV/EBIT
0.00 53.31 11.80 12.19 45.47 15.04 19.63 38.87 14.18 12.46
Other line items

Show all line items

Columns are period end dates · fundamentals updated 5 Nov 2026